---
title: New medication slows Parkinson progression
nct_id: NCT06976268
phase: PHASE2, PHASE3
status: RECRUITING
sponsor: Biohaven Therapeutics Ltd.
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06976268"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06976268"
last_fetched: "2026-05-10T14:05:43.316Z"
source: "Parkinson's Pathways (curated)"
---
# New medication slows Parkinson progression

**Goal (in five words):** New medication slows Parkinson progression

**Official Title:** A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease

**Trial ID:** [NCT06976268](https://clinicaltrials.gov/study/NCT06976268)

## Key Facts

- **Phase:** PHASE2, PHASE3
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Biohaven Therapeutics Ltd.
- **Target Enrollment:** 550 participants
- **Start Date:** 2025-05-28
- **Completion Date:** 2027-08
- **Conditions:** Parkinson Disease
- **Interventions:** BHV-8000, BHV-8000, Placebo
- **Intervention Types:** DRUG

## Summary For Families

The goal is to see whether BHV-8000 can slow or alter disease progression in people with very early Parkinson's, aiming to reduce the underlying brain changes that lead to worsening motor symptoms before standard Parkinson's drugs are started. BHV-8000 is an experimental oral medication thought to act on biological pathways tied to neuron dysfunction and loss; participants are randomly given BHV-8000 or placebo so researchers can measure its effects without the influence of levodopa or other PD treatments. The trial is looking for people aged 40 to 85 with a clinician-confirmed probable idiopathic Parkinson's diagnosis within the last two years, who are not current smokers and are not taking Parkinson's medications, with other significant CNS conditions excluded.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 85 Years
- **Sex:** ALL

### Full Criteria

```
Key Inclusion Criteria:

* Male or female participants 40 to 85 years of age, inclusive, at the time of informed consent.
* Meet the diagnostic criteria for "Probable PD" as assessed on the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PD as assessed by the Investigator.
* Have a clinician-documented diagnosis of idiopathic PD with an onset within 2 years of the Screening Visit

Key Exclusion Criteria:

* Medical history indicating a Parkinsonian syndrome other than idiopathic PD, including, but not limited to, progressive supranuclear gaze palsy, multiple system atrophy, drug-induced Parkinsonism, essential tremor, or primary dystonia.
* Diagnosis of clinically significant central nervous system (CNS) disease other than PD.
* Participants who are current smokers (defined as smoking \[in any form, e.g., tobacco smoke, electronic cigarettes, etc.\] )
* Treatment with PD medication(s)
* Any other condition(s) that may compromise participant safety, interfere with study conduct, or jeopardize the potential proper interpretation of study results, in the opinion of the investigator.
```

## Locations (15)

- Site-049, Birmingham, Alabama, United States _(33.5207, -86.8025)_
- Site-041, Los Angeles, California, United States _(34.0522, -118.2437)_
- Site-031, Farmington, Connecticut, United States _(41.7198, -72.8320)_
- Site-028, New Haven, Connecticut, United States _(41.3081, -72.9282)_
- Site-038, Atlantis, Florida, United States _(26.5909, -80.1009)_
- Site-017, Boca Raton, Florida, United States _(26.3587, -80.0831)_
- Site-051, Maitland, Florida, United States _(28.6278, -81.3631)_
- Site-027, Chicago, Illinois, United States _(41.8500, -87.6500)_
- Site-071, Boston, Massachusetts, United States _(42.3584, -71.0598)_
- Site-015, Farmington Hills, Michigan, United States _(42.4853, -83.3772)_
- Site-044, Chesterfield, Missouri, United States _(38.6631, -90.5771)_
- Site-005, New York, New York, United States _(40.7143, -74.0060)_
- Site-091, Portland, Oregon, United States _(45.5234, -122.6762)_
- Site-043, Round Rock, Texas, United States _(30.5083, -97.6789)_
- Site-007, Bellevue, Washington, United States _(47.6104, -122.2007)_

## Central Contacts

- Chief Medical Officer — (CONTACT) — 203-404-0410 — clinicaltrials@biohavenpharma.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06976268*  
*HTML version: https://parkinsonspathways.com/trial/NCT06976268*  
*Source data: https://clinicaltrials.gov/study/NCT06976268*